Naitive® Technologies, a medical technology company redefining care pathways for musculoskeletal health, today announced a new research collaboration with the JIS Research Institute of JIS Orthopedics, a leading orthopedic clinic in the Midwest, dedicated to positive patient outcomes, musculoskeletal innovation, and setting the global standard for orthopedic care.

The collaboration will use retrospective data to investigate the prevalence of low bone mineral density (BMD) in patients at JIS Orthopedics, using Naitive’s FDA-designated Breakthrough device, OsteoSight™. The study will also examine the association between OsteoSight’s findings of low BMD, a key indicator of bone health, with surgical outcomes in patients who have undergone primary total hip arthroplasty (THA).

Low BMD is highly prevalent among patients undergoing joint replacement surgery[1], however preoperative bone health assessments remain rare. Evidence indicates that 90% of high-risk patients do not receive appropriate treatment, and 88% do not undergo adequate bone health evaluation prior to surgery[2]. As bone quality plays a major role in implant fixation, healing, and the risk of periprosthetic fractures, earlier identification of low BMD presents a significant opportunity to improve surgical planning and outcomes.

OsteoSight enables the opportunistic assessment of low BMD using standard X-rays acquired for other clinical indications. It can be embedded into routine orthopedic clinical workflows without changing existing imaging protocols.

The study, led by Principal Investigator and JIS Research Institute’s Medical Director, Dr. David Crawford, who was recently ranked in the top 1% of all orthopedic surgeon researchers in the country, will leverage JIS Orthopedics’ large, retrospective longitudinal joint replacement dataset. The research aims to assess how opportunistic BMD assessment, provided by OsteoSight, might inform preoperative planning and support surgeons in developing intervention strategies to reduce implant failure, delayed healing, and revision surgeries.

“JIS Research Institute is excited to collaborate with Naitive on this research project to better understand the prevalence of osteopenia and osteoporosis in our patient population as well as the correlation to the outcomes in total hip arthroplasty” said Dr. David Crawford, Medical Director of JIS Research Institute.

The collaboration with JIS Research Institute represents a critical step in validating the clinical utility of AI-driven BMD assessment in orthopedic settings.

“OsteoSight allows orthopedists to extract critical insights from standard-of-care X-rays that would otherwise go unnoticed,” said Dr. Will Briggs, CEO of Naitive Technologies. “By embedding advanced technology into existing orthopedic workflows, we are expanding the clinical value of routine imaging while supporting orthopedic practices to provide more comprehensive care for their patients and improve surgical outcomes.”

About Joint Implant Surgeons (JIS) Orthopedics.

Founded in 1972, JIS Orthopedics has been an innovative leader in orthopedics with nationally recognized physicians. With two Ohio clinic locations in New Albany and St. Clairsville and more than 150 years of collective experience, JIS specializes in total joint replacements, sports medicine, and general orthopedics. Their team of ten physicians and more than 80 staff members is committed to getting patients back to living a vibrant, pain-free lifestyle. JIS Orthopedics is a Partner Practice of OrthoAlliance.

References:

[1] https://pubmed.ncbi.nlm.nih.gov/24085661/

[2] https://pubmed.ncbi.nlm.nih.gov/35447275/

Disclaimer: This press release is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for any medical concerns or treatment options related to osteoporosis. OsteoSight is not FDA-cleared and should be considered an investigational device.